The assay uses antibodies that recognize influenza viral antigens in a respiratory specimen. When binding occurs, the antigen-antibody complexes migrate across a membrane by lateral flow. Their accumulation at a designated location produces a visible line, converting a molecular recognition event into a result that can be read without specialized laboratory instrumentation.
A negative result can occur when the specimen contains too little viral material for the antigen-detection system to produce a visible signal. This limitation makes the result dependent on the amount of detectable virus present. Symptoms, exposure history, and follow-up testing therefore help clinicians judge whether a negative finding is conclusive.
Separate visible lines allow the assay to indicate whether influenza A or influenza B antigen was detected. This distinction reflects selective antibody binding to viral targets associated with each group. In immunology and infection studies, the result provides a rapid antigen-level indication that can support clinical assessment without requiring the test to identify every feature of the virus.
A respiratory specimen is introduced into the lateral-flow test system, where any detectable influenza antigen can bind the assay antibodies. The resulting complexes move across the membrane and generate a visible line within minutes. The workflow therefore links specimen testing, antibody recognition, membrane migration, and visual interpretation in a single point-of-care process.
Rapid results can help clinicians assess a patient while decisions about antiviral treatment and infection-control measures are still relevant. Because the test is performed at the point of care, its value lies in providing timely evidence rather than waiting for a later assessment. Interpretation remains strongest when combined with symptoms and exposure history.
A negative rapid antigen result does not by itself exclude influenza, particularly when viral levels are low or the clinical picture suggests infection. Clinicians can compare the finding with symptoms and exposure history and consider follow-up testing. This cautious interpretation supports more reliable treatment decisions and helps avoid weakening infection-control measures solely because of one negative result.